Ece Erbağcı
8PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Mar 25, 2026
Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence.Sema Koç Yıldırım, Saadet Miray Ayyıldız, Neslihan Demirel Öğüt
|May 22, 2025
Serum C-Reactive Protein as a Potential Indicator for Screening Fecal Calprotectin in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Cross-Sectional Cohort Study.Neslihan Demirel Öğüt, Rahşan Ilıkçı Sağkan, Rabia Arıcı
|Jul 01, 2024
Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): Real-world data from a tuberculosis-endemic country.Ece Erbağcı, Sema Koç Yıldırım, Fatma Aslı Hapa
|Mar 03, 2023
Omalizumab treatment in combination with any other biologics: Is it really a safe duo?Sema Koç Yıldırım, Ece Erbağcı, Aslı Hapa
|Nov 29, 2022
Merkel cell number and distribution, and CD200 expression in patients with lichen planopilaris and discoid lupus erythematosus.Ece Erbağcı, Ayşen Karaduman, Özay Gököz
|Feb 24, 2022
Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium?Sema Koç Yıldırım, Ece Erbağcı, Neslihan Demirel Öğüt
Pageof 2
